Table 4.

Averted DALY and cost on CVD events prevented by controlling hypertension according to 2017 ACC/AHA guideline

	Stroke	CHD	Totalg
Number of prevented eventa	151 000 (131 130, 170 140)	55 000 (47 430, 61 540)	206 000 (178 560, 231 680)
DALY per eventb	4.82 (3.39, 8.29)	12.60 (9.24, 19.13)	6.72 (4.78, 11.20)
Averted DALYc	726 000 (444 531, 1 410 461)	688 000 (438 253, 1 177 260)	1 414 000 (882 784, 2 587 721)
Annual cost per event (US dollar)d	1178.1 (994.5, 1786.7)	2485.4 (1069.0, 4418.7)	–
Reduced annual cost (US dollar, million)e	177.6 (130.4, 304.0)	135.6 (50.7, 271.9)	313.2 (181.1, 575.9)
Reduced lifetime cost (US dollar, million)f	2130.6 (1564.9, 3648.0)	1627.5 (608.4, 3263.1)	3758.2 (2173.3, 6911.1)

Data are presented as mean (95% CI).

Abbreviations: CHD, coronary heart disease; DALY, disability adjusted of life year.

^aSuppose 4.7/1000 strokes and 1.7/1000 coronary heart disease events each year in hypertensive patients with pharmaceutical treatments could be prevented based on Felodipine Event Reduction study.2 The number of prevented event was calculated as patients with drug therapy multiplies 4.7/1000 for strokes or 1.7/1000 for CHD.

^bThe DALYs was 44 947 064.55 for stroke, and 38 060 559.75 for CHD based on GDB (Ref. 15); the prevalence was 9 330 000 (5 420 000, 13 240 000) for stroke, and 3 020 000 (1 990 000, 4 120 000) for CHD from Table S2. So, DALY per event was 4.82 (3.39‐8.29) for stroke, 12.60 (9.24‐19.13) for CHD, and 6.72 (4.78‐11.20) for total.

^cAverted DALY = Number of prevented event × DALY per event.

^dValues were cited from China Health Statistics Yearbook, 2013 (Ref. 16).

^eReduced annual cost = Annual cost per event × Number of prevented event.

^fReduced lifetime cost = (life expectancy estimated by the World Bank [76 y] (Ref. 14) − age of hypertensive patients who recommended antihypertensive drugs but not receive drug treatment in our study [64 y]) × reduced annual costs.

^gThe value of the Column of “Total” = the Column of “Stroke” + “CHD”.